Partnering with VantAI could give Halda a source of target-effector pairs for its next wave of prospects. The deal could be ...

Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures, but the company ...

China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine ...

Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise. | Gene therapy biotech Kriya ...

After an FDA rejection in May, Stealth BioTherapeutics has resubmitted a new drug application for its investigational ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal ...

In an update to their guidelines for treating high blood pressure, a group of cardiovascular medical societies has included a ...

Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. | ...

After years of striking acquisitions to build up its site network, Headlands Research has now been bought itself.  | After ...

Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...